Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Thoracic 2

Conditions

Melanoma 7Colitis 3Carcinoma, Non-Small-Cell Lung 2Urogenital Neoplasms 1Skin Neoplasms 1Precancerous Conditions 1Lung Neoplasms 1Hepatitis C 1Hepatitis 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Renal Cell 1

Interventions

Infliximab 3vedolizumab 2Fecal Microbiota Transplantation 2Prednisone 1Photopheresis 1Mycophenolic Acid 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Methoxsalen 1Loperamide 1LDP-02 1Immunoglobulin G 1Disulfides 1CT-P13 1Azathioprine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Colitis × Infliximab × Dermatologic × Clear all
NCT07619898 2026-06-02

PHOENIX-ECP

Therakos LLC

Phase 2 Not yet recruiting
112 enrolled
Dermatologic

Colitis, Hepatitis, Melanoma

NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡